Introduction Hemophilia A and B are disorders associated with the deficit of coagulation
factors VIII and IX. Objective Was to determine the incidence of complications in a cohort of …

The development of inhibitors against factor VIII (FVIII) concentrates is a severe complication
of treatment for patients with haemophilia. We investigated annualized bleeding rates …

Background: The appearance of inhibitory antibodies against antihemophilic factors is one
of the most serious complications related to hemophilia. Objective: The objective of this …

Background: The treatment of hemophilia generates a disproportionally large economic
impact relative to its prevalence. Objective: To determine the economic impact of hemophilia …

Introduction Brazil is one of the countries with the largest population of people with
hemophilia (PwH) worldwide. In this scoping review, we aim to investigate the Brazilian …

ABSTRACT Introduction: In Africa, where access to diagnosis and treatment of hemophilia is
the lowest in the world, prophylaxis is rarely used in preference to on-demand treatment …

The purpose of this narrative review was to provide an overview that allows readers to
improve their understanding of hemophilia A, which is considered a genetic disease with a …

Hemophilia A is an inherited disorder characterized by deficiency of coagulation factor VIII,
which predisposes patients to bleeding events. Treatment is based on replacement of the …

The Spanish Epidemiological Study in Haemophilia carried out in 2006 enrolled 2400
patients [2081–86.7% with haemophilia A (HA) and 319–13.3% with haemophilia B]; 465 of …

Prophylaxis with factor VIII concentrates is the cornerstone of treatment for severe
hemophilia A. In children, early onset of primary and secondary prophylaxis is the gold …